Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis

Keyphrases

• Alamar Blue Assay 20%
• Anti-hepatic Fibrosis 20%
• Antifibrogenic Effect 20%
• Apoptosis 20%
• Cell Apoptosis 20%
• Cell Death 20%
• Cell Proliferation 60%
• Cellular Protein Expression 20%
• Cleaved caspase-3 20%
• Dose Effect 20%
• Enhancement Effect 100%
• Extracellular Matrix Protein 1 (ECM1) 60%
• Fibronectin 40%
• Flow Cytometry 20%
• Hepatic Fibrosis 100%
• Hepatic Stellate Cell Activation 40%
• Hepatic Stellate cells-T6 40%
• Hepatocyte Cell Line 20%
• Human Hepatoma Cells 20%
• IC50 Value 20%
• Immunoblot 20%
• Immunofluorescence Staining 20%
• Induced Apoptosis 20%
• Liver Fibrosis 20%
• LX-2 20%
• LX-2 Cells 40%
• Marker Proteins 20%
• Myofibroblast 20%
• Natural Compounds 20%
• Oridonin 100%
• Propidium Iodide 20%
• Protein Deposition 20%
• Protein Type 20%
• S Phase Cell Cycle Arrest 20%
• Stellate Cells 20%
• Transforming Growth Factor-β 20%
• Type I Collagen 40%
• YO-PRO-1 20%
• α-smooth muscle Actin (α-SMA) 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Cancer Growth Factor 20%
• Caspase 3 20%
• Cell Protein 20%
• Collagen Type 1 40%
• Enzyme-Linked Immunosorbent Assay 20%
• Fibronectin 40%
• Fibrosis 20%
• Flow Cytometry 20%
• IC50 20%
• Liver Fibrosis 100%
• Matrix Protein 20%
• Natural Product 20%
• Oridonin 100%
• Propidium Iodide 20%
• Protein P53 20%
• Scleroprotein 40%
• Smooth Muscle Actin 20%
• Western Blot 20%